menu
    • menu
    [{"orgOrder":0,"company":"Orgenesis","sponsor":"Tamir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Ranpirnase","moa":"tRNA hydrolytic enzyme","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Orgenesis","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"Orgenesis \/ Orgenesis","highestDevelopmentStatusID":"7","companyTruncated":"Orgenesis \/ Orgenesis"},{"orgOrder":0,"company":"Orgenesis","sponsor":"Edith Wolfson Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Tumor infiltrating lymphocytes","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Orgenesis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Orgenesis \/ Orgenesis","highestDevelopmentStatusID":"1","companyTruncated":"Orgenesis \/ Orgenesis"},{"orgOrder":0,"company":"Orgenesis","sponsor":"Leidos","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Ranpirnase","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Orgenesis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Orgenesis \/ Leidos","highestDevelopmentStatusID":"4","companyTruncated":"Orgenesis \/ Leidos"},{"orgOrder":0,"company":"Orgenesis","sponsor":"Educell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"CAR-T cell therapy","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Orgenesis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Orgenesis \/ Orgenesis","highestDevelopmentStatusID":"1","companyTruncated":"Orgenesis \/ Orgenesis"},{"orgOrder":0,"company":"Orgenesis","sponsor":"Koligo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Autologous pancreatic islets cells","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Orgenesis","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","amount2New":0.02,"dosageForm":"","sponsorNew":"Orgenesis \/ Orgenesis","highestDevelopmentStatusID":"12","companyTruncated":"Orgenesis \/ Orgenesis"},{"orgOrder":0,"company":"Orgenesis","sponsor":"Orgenesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Autologous mesenchymal stem cells infected oncolytic virus","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Orgenesis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Orgenesis \/ Orgenesis","highestDevelopmentStatusID":"6","companyTruncated":"Orgenesis \/ Orgenesis"}]

    Find Clinical Drug Pipeline Developments & Deals by Orgenesis

    Menu

    Orgenesis

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Orgenesis

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Orgenesis

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous mesenchymal stem cells infected oncolytic virus

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Hospital Infantil Universitario Niño Jesús

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            The Collaboration is Focused on Advancing Clinical Development and Commercialization of the Oncolytic Virus-Ba...

                            Details : The POCare Platform has been designed by Orgenesis to enable hospitals and healthcare facilities globally to develop, optimize and manufacture cell and gene therapies throughout a POC Network of global healthcare facilities.

                            Brand Name : Celyvir

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 11, 2021

                            Lead Product(s) : Autologous mesenchymal stem cells infected oncolytic virus

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Hospital Infantil Universitario Niño Jesús

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Orgenesis

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Orgenesis

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous pancreatic islets cells

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Approved

                            Recipient : Koligo Therapeutics

                            Deal Size : $16.3 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Orgenesis Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell Therapies

                            Details : Following closing of the Transaction, Orgenesis plans to accelerate the commercial scaleup of KYSLECEL throughout the United States and, subject to regulatory and logistical considerations, in international markets as well.

                            Brand Name : Kyslecel

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 29, 2020

                            Lead Product(s) : Autologous pancreatic islets cells

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Approved

                            Recipient : Koligo Therapeutics

                            Deal Size : $16.3 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Orgenesis

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Orgenesis

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR-T cell therapy

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Educell

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orgenesis Enters Collaboration Agreement with Educell

                            Details : The agreement is part of the Orgenesis strategy of growing and expanding the POCare Network. The first collaboration under the agreement will focus on the clinical development of CAR-T and whole cell-based vaccine platform for use in cancer immunotherapi...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 14, 2020

                            Lead Product(s) : CAR-T cell therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Educell

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Orgenesis

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Orgenesis

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranpirnase

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Leidos

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orgenesis and Leidos Collaborate on Potential Treatment for COVID-19

                            Details : Orgenesis has entered into a preliminary, non-binding term sheet with Leidos to develop and potentially obtain FDA marketing approval of Orgenesis’ Ranpirnase for the systemic treatment of patients suffering with SARS-CoV-2 the virus that causes COVID-...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 24, 2020

                            Lead Product(s) : Ranpirnase

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Leidos

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Orgenesis

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Orgenesis

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tumor infiltrating lymphocytes

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Edith Wolfson Medical Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orgenesis to Collaborate with The Edith Wolfson Medical Center to Conduct Clinical Study Using Orgenesis’ Pr...

                            Details : Clinical study will be undertaken with goal of utilizing and validating a number of Orgenesis’ proprietary POCare Technologies, including an automated cell culturing system for the generation and expansion tumor infiltrating lymphocytes for use in adop...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 01, 2020

                            Lead Product(s) : Tumor infiltrating lymphocytes

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Edith Wolfson Medical Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Orgenesis

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Orgenesis

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranpirnase

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Recipient : Tamir Biotechnology

                            Deal Size : $19.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Orgenesis to Acquire Tamir Biotechnology for Broad Spectrum Antiviral Platform

                            Details : Orgenesis and TamirBio plan to combine ranpirnase with Bioxomes, which have shown the ability to fuse with cell membranes and deliver an intracellular cargo, in a similar manner to natural exosomes.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 14, 2020

                            Lead Product(s) : Ranpirnase

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Tamir Biotechnology

                            Deal Size : $19.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth